Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO survey for Dr Hazen click here
Read more/less

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

MEBO Research Clinical Trials

Sunday, June 30, 2019

Ubiome MEBO study and Bloodtype

MEBO-UBIOME stool DNA study update
Ubiome kindly gave MEBO many Explorer Stool DNA test kits to try and profile our community for this test.

Professor Irene Gabashvili, PhD., MEBO Scientific Director is conducting the MEBO - UBIOME community study on people with METABOLIC MALODOR, other MALODOR types, and PATM.
The full paper will be completed soon.

As it draws to a close Irene can look at the stats and show points of interest.

In Irene's recent AURAMETRIX blog post, Irene has focused on BLOODTYPE among the MEBO community and the world average.

Current MEBO-Ubiome Study participant totals :

Each participant was allowed to get 4 free Ubiome Stool Explorer test kits.
43 returned all samples and completed the questionaire.
8 returned 1 sample.
40+ got kits but didn't do the questionaire.

It's not too late to complete the trial (for those who already signed up).
It's too late for new participants to take part.

Prof Irene's provisional stats on Bloodtype among the MEBO group.



Quote from Irene on the results
The most common blood type in the world is O+ (~36.4%). About 4.3% have blood type O-. Blood types A+, B+ and AB+ are prevalent at approximately 28.3%, 20.6% and 5.1% respectively. Percentages for A-, B- and AB- are 3.5%, 1.4% and 0.5%.
These percentages may differ by country, but it appears that A- and B- blood types are less prevalent in MEBO population, while O and AB are more common.


Symptom-less diet was also different for different blood group types. Average Quality of Life score was 83, 92, 95 and 91 for O, A, B and AB groups, respectively (best for B, then A, worst for O), while MEBO symptoms were also least severe and most controllable for B- type, but worse for those with A antigens. The widest variation in MEBO symptoms was in the AB group.
Irene's full post on her AURAMETRIX blog can be seen here :  Aurametrix Blog Post
 

get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

0 comments:

Post a Comment